Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2385 November 2025

Reg No: First Names: First Names:	
Name: Surname: Surname:	
Address: DOB: Address:	
Fax Number: Fax Number:	
Dasatinib	
Initial application Applications only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate) The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase or The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL) or The patient has a diagnosis of CML in chronic phase and Patient has documented treatment failure* with imatinib or Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib or Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system	
Renewal Current approval Number (if known):	
Lack of treatment failure while on dasatinib* and Dasatinib treatment remains appropriate and the patient is benefiting from treatment	
Note: *treatment failure for CML as defined by Leukaemia Net Guidelines.	

I confirm the above details are correct and that in signing this form I understand I may be audited.